Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.
Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H. Hasford J, et al. Among authors: pfirrmann m. J Natl Cancer Inst. 1998 Jun 3;90(11):850-8. doi: 10.1093/jnci/90.11.850. J Natl Cancer Inst. 1998. PMID: 9625174
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure.
Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H, Siegert W, Finke J, Ehninger G, Holler E, Berger U, Pfirrmann M, Muth A, Zander A, Fauser AA, Heyll A, Nerl C, Hossfeld DK, Löffler H, Pralle H, Queisser W, Tobler A. Hehlmann R, et al. Among authors: pfirrmann m. Blood. 1999 Dec 1;94(11):3668-77. Blood. 1999. PMID: 10572078 Free article. Clinical Trial.
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiss J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H; German CML-Study Group. Hehlmann R, et al. Among authors: pfirrmann m. Leukemia. 2003 Aug;17(8):1529-37. doi: 10.1038/sj.leu.2403006. Leukemia. 2003. PMID: 12886239 Clinical Trial.
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial.
Buesche G, Hehlmann R, Hecker H, Heimpel H, Heinze B, Schmeil A, Pfirrmann M, Gomez G, Tobler A, Herrmann H, Kappler M, Hasford J, Buhr T, Kreipe HH, Georgii A. Buesche G, et al. Among authors: pfirrmann m. Leukemia. 2003 Dec;17(12):2444-53. doi: 10.1038/sj.leu.2403172. Leukemia. 2003. PMID: 14562117 Clinical Trial.
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia.
Buesche G, Freund M, Hehlmann R, Georgii A, Ganser A, Hecker H, Heimpel H, Fonatsch C, Heinze B, Pfirrmann M, Holgado S, Schmeil A, Tobler A, Hasford J, Buhr T, Kreipe HH; German CML Study Group. Buesche G, et al. Among authors: pfirrmann m. Leukemia. 2004 Sep;18(9):1460-7. doi: 10.1038/sj.leu.2403451. Leukemia. 2004. PMID: 15284854
91 results